entertainment -WSS

entertainment

author：explore 2025-09-06 03:53:42 - browse：28

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： What health policies could hitch a ride on a spending bill?

hotspot

explore

WSS

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Hospitals use virtual reality to design more inclusive rooms for kids

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

Cancer diagnosis changes perspective doctor, former hospital CEO

Readout Newsletter: Zepbound, Valneva's vaccine, and more

FDA reorg will put new emphasis on investigations, sources say

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

More regulation could be coming for drug ads

In Memoriam: Notable people who died in 2023

Germany receives 178 compensation applications from gay servicepeople over discrimination

DIEP, the 'gold standard' of breast reconstruction, is under threat

Carbon Health diabetes program, a test of data

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Walensky prepares to leave CDC — and Congress — behind

Former Georgia lieutenant governor says he received grand jury subpoena

focus

How state and local governments are sidelining science

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

After decades in use, heart stents finally beat placebo

FDA reorg will put new emphasis on investigations, sources say

Medical school prerequisites are outdated

Healthy food access boosts outcomes in two studies

hotspot

Wikipedia

explore

explore